Previous close | 12.69 |
Open | 12.59 |
Bid | 12.53 x 1100 |
Ask | 12.59 x 800 |
Day's range | 12.50 - 12.63 |
52-week range | 12.01 - 24.00 |
Volume | |
Avg. volume | 169,820 |
Market cap | 337.663M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 32.33 |
LOS ALTOS, Calif., May 21, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced the expansion of the Company’s leadership team with the addition of industry veteran Michael Hanley as chief operating officer (COO). Mr. Hanley brings over twenty-five years of leadership experience in the life sciences industry, with established expertise across corporate operations, product development, strategy, and commercialization, with relevant expertise in CNS/neuroscience-focused companies. A
LOS ALTOS, Calif., May 14, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.
LOS ALTOS, Calif., May 09, 2024--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) today announced upcoming data presentations that highlight the company’s precision psychiatry pipeline and biomarker-based analyses at the Society of Biological Psychiatry (SOBP) and American Society of Clinical Psychopharmacology (ASCP) Annual Meetings, to take place May 9-11 in Austin, TX, and May 28-31 in Miami Beach, FL, respectively.